Physician profile
Jennifer C Lai
NPI 1649397241
$70,313.57
in general payments reported to CMS, 2019-2025
11 companies · $22K in 2025
The $22K reported for 2025 was more than what 84% of Transplant Hepatology providers received nationally (typical 2025 total: $508).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $112 · 2020: $750 · 2021: $4,320 · 2022: $13K · 2023: $28K · 2024: $1,932 · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $39K · Travel and Lodging: $12K · Food and Beverage: $1,034 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $38,763.50 |
| Travel and Lodging | $11,960.01 |
| Food and Beverage | $1,034.16 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $51,450.43 | 2021-2025 | |
| Boehringer Ingelheim International Gmbh | $14,928.95 | 2025 | |
| Nestle Healthcare Nutrition INC. | $2,723.42 | 2022-2023 | |
| Biomarin Pharmaceutical INC. | $750.00 | 2020 | |
| Sanofi-Aventis U.S. LLC | $147.30 | 2024 | |
| Madrigal Pharmaceuticals | $102.45 | 2025 | Rezdiffra |
| Janssen Biotech, INC. | $99.00 | 2023 | Stelara |
| Salvin Dental Specialties, INC. | $91.10 | 2019 | |
| Novartis Pharmaceuticals Corporation | $20.92 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Lai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.